Filtered By:
Drug: Tamoxifen
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 50 results found since Jan 2013.
Abstract PD4-07: Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population study
Conclusions: The occurrence of MI is very low in this cohort (4.4%), reassuring the clinicians that the older adults with comorbidities may not be at a higher risk of MI with adjuvant endocrine therapy. However, the confidence interval for the hazard ratio of AIs vs Tamoxifen is very wide, indicating that a larger sample may be needed for the power of the study to be conclusive.Citation Format: Kamaraju S, Smith E, Shi Y, Laud P, Neuner J. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population study [abstract]. In: Proceedings of the Thirty-Ninth Annual C...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: S Kamaraju, E Smith, Y Shi, P Laud, J Neuner Tags: Poster Discussion Abstracts Source Type: research
Abstract P2-01-23: Long-term follow-up of persistent breast dermopigmentation after sentinel lymph node identification using superparamagnetic iron oxide particles (SIENNA+(R))
Patients with breast cancer (BC) and those at high risk for BC are often reluctant to initiate Tamoxifen (Tam) due to potential adverse events (AEs) such as deep vein thrombosis (DVT), pulmonary embolus (PE), acute ischemic stroke (AIS), myocardial infarction (MI) and endometrial cancer (EC). Some decline this life saving therapy due to fear of AEs. AE rates from RCTs are low, but AE rates in the general population are not well documented.Methods: The MarketScanR database (2010-2013) was searched for patients aged 30-64 with a prescription of Tam active for more than 120 days. Patients with prior DVT, PE, AIS, MI or EC wer...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: K Hannebicque, L Boulanger, E Bogart, S Giard, MP Chauvet, JL Houpeau Tags: Poster Session Abstracts Source Type: research
Estrogens and Coronary Artery Disease: New Clinical Perspectives.
Abstract
In premenopausal women, endogenous estrogens are associated with reduced prevalence of arterial hypertension, coronary artery disease, myocardial infarction, and stroke. Clinical trials conducted in the 1990s such as HERS, WHI, and WISDOM have shown that postmenopausal treatment with horse hormone mixtures (so-called conjugated equine estrogens) and synthetic progestins adversely affects female cardiovascular health. Our understanding of rapid (nongenomic) and chronic (genomic) estrogen signaling has since advanced considerably, including identification of a new G protein-coupled estrogen receptor (GPER),...
Source: Advances in Pharmacology - July 29, 2016 Category: Drugs & Pharmacology Authors: Meyer MR, Barton M Tags: Adv Pharmacol Source Type: research
Update on Breast Cancer Risk Reduction Therapy
Abstract
In women at increased risk of breast cancer age ≥35 years, the selective estrogen receptor modulator (SERM) tamoxifen should be discussed as an option to reduce the risk of estrogen receptor (ER)-positive breast cancer. In postmenopausal women, raloxifene, anastrozole, and exemestane should also be discussed as options for breast cancer risk reduction. Risk reduction with SERMs continues for at least 10 years in both premenopausal and postmenopausal women. Tamoxifen is not recommended for women with a history of deep vein thrombosis, pulmonary embolus, stroke, transient ischemic attack, or during prol...
Source: Current Breast Cancer Reports - July 19, 2016 Category: Cancer & Oncology Source Type: research
AIs Not Tied to Cardiac Ischemia, Stroke in Breast CA PatientsAIs Not Tied to Cardiac Ischemia, Stroke in Breast CA Patients
Breast cancer patients on aromatase inhibitors (AIs) do not seem to be at greater risk for cardiac ischemia or stroke compared with those taking tamoxifen, researchers have found. Reuters Health Information
Source: Medscape Medical News Headlines - May 2, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
No increased risk of fatal cardiovascular events for breast cancer patients on newer hormone therapy
The use of aromatase inhibitors, hormone-therapy drugs used to treat patients with breast cancer, was not associated with an increased risk of fatal cardiovascular events, including heart attacks or stroke, compared with tamoxifen, another commonly prescribed anti-cancer drug that works on hormones and which has been associated with a serious risk of stroke, report investigators.
Source: ScienceDaily Headlines - April 21, 2016 Category: Science Source Type: news
No increased risk of fatal CV events for breast cancer patients on newer hormone therapy
(Kaiser Permanente) In a new study from Kaiser Permanente, researchers found the use of aromatase inhibitors, hormone-therapy drugs used to treat patients with breast cancer, was not associated with an increased risk of fatal cardiovascular events, including heart attacks or stroke, compared with tamoxifen, another commonly prescribed anti-cancer drug that works on hormones and which has been associated with a serious risk of stroke.
Source: EurekAlert! - Cancer - April 21, 2016 Category: Cancer & Oncology Source Type: news
Endothelial β-Catenin Signaling Is Required for Maintaining Adult Blood-Brain Barrier Integrity and CNS Homeostasis.
CONCLUSIONS: -These results demonstrate the prerequisite role of endothelial β-catenin in maintaining the integrity of adult BBB. The results suggest that BBB dysfunction secondary to defective β-catenin transcription activity is a key pathogenic factor in hemorrhagic stroke, seizure activity and CNS inflammation.
PMID: 26538583 [PubMed - as supplied by publisher]
Source: Circulation - November 4, 2015 Category: Cardiology Authors: Tran KA, Zhang X, Predescu D, Huang X, Machado RF, Göthert JR, Malik AB, Valyi-Nagy T, Zhao YY Tags: Circulation Source Type: research
Abstract 1341: Endocrine deprivation therapy increases the sensitivity of breast cancer cells to T cell-mediated lysis independently of estrogen receptor or androgen receptor status
Estrogen deprivation therapy has been used as the first line adjuvant hormonal therapy for breast cancer for over 20 years. Tamoxifen, the first drug discovered to inhibit estrogen receptor signaling, is used to treat premenopausal women with estrogen receptor positive tumors. Although tamoxifen can be therapeutic in most women with estrogen receptor positive tumors, some women do not respond and others eventually develop resistance. In addition, tamoxifen has minimal effect on the growth of estrogen receptor negative tumors, including triple negative breast cancer, which has the poorest prognosis. Furthermore, prolonged a...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kwilas, A. R., Ardiani, A., Gameiro, S. R., Hodge, J. W. Tags: Immunology Source Type: research
Abstract PD4-2: Cardiovascular toxicity following aromatase inhibitor use in 13,273 survivors cared for in a HMO
Discussion
These results indicate that variation exists in the type of CVD events that occur in breast cancer patients receiving AIs in comparison to tamoxifen users. For example, the risk of ischemic disease or stroke was not elevated in those who used AIs only versus TAM users. However, overall CVD events were greater in women who used AIs only (or sequentially after TAM), especially if they received left-sided breast irradiation. While these observational study results require cautious interpretation, they provide a basis for comparing the benefits and risks of endocrine treatments.
Citation Format: Reina Haque, Joanne ...
Source: Cancer Research - April 30, 2015 Category: Cancer & Oncology Authors: Haque, R., Schottinger, J. E., Shi, J., Chung, J., Avila, C., Amundsen, B., Chlebowski, R. T. Tags: Poster Discussion Abstracts Source Type: research
This Vitamin Could Save Your Life
For years, I’ve recommended that my patients take a special family of super-nutrients with the power to boost their health and save their lives in at least a half a dozen ways.
I’m talking about tocotrienols, an especially potent form of vitamin E.
Tocotrienols, which comprise four out of the eight types of vitamin E, are powerful antioxidants that until recently were ignored by mainstream medicine.
But the patients at my wellness clinic and regular readers of my newsletter will know that I’ve recommended them as a critical nutrient for years.
And I do it because almost daily I observe the effects of the...
Source: Al Sears, MD Natural Remedies - March 26, 2015 Category: Complementary Medicine Authors: Dr. Al Sears Tags: Anti-Aging Nutrition antioxidants brain Cancer heart heart disease nutrients supplements vitamins Source Type: news
Vascular Stat3 Promotes Angiogenesis and Neuroplasticity Long-Term After Stroke.
CONCLUSIONS: -Endothelial Stat3 regulates angiogenesis, axon growth and ECM-remodeling and is essential for long-term recovery after stroke. It might serve as a potent target for stroke treatment after the acute phase by fostering angiogenesis and neuroregeneration.
PMID: 25794850 [PubMed - as supplied by publisher]
Source: Circulation - March 20, 2015 Category: Cardiology Authors: Hoffmann CJ, Harms U, Rex A, Szulzewsky F, Wolf SA, Grittner U, Lättig-Tünnemann G, Sendtner M, Kettenmann H, Dirnagl U, Endres M, Harms C Tags: Circulation Source Type: research
Microvascular Lesions by Estrogen-Induced ID3: Its Implications in Cerebral and Cardiorenal Vascular Disease
We present evidence for how ID3 overexpression in endothelial cells contributes to the development of an estrogen-induced neovascular phenotype with an additional focus on Pyk2 kinase. Our data showed that ID3 overexpression increased neovascularization, cell migration, and spheroid growth of human cerebral microvascular endothelial cells, hCMEC/D3. ID3-overexpressing cells showed significant estrogen-induced G2/M phase transition. Estrogen treatment increased both ID3 phosphorylation; total protein that was inhibited by tamoxifen, and Pyk2-mediated estrogen-induced ID3 mRNA expression. These findings suggest that Pyk2 sig...
Source: Journal of Molecular Neuroscience - February 7, 2015 Category: Neuroscience Source Type: research
Risk-Benefit Profiles of Women Using Tamoxifen for Chemoprevention
Conclusions:
While the majority of women who used tamoxifen for primary prevention of breast cancer were likely to benefit, substantial discontinuation of tamoxifen before five years and use by women at risk of serious side effects may attenuate benefits for breast cancer prevention.
Source: JNCI - December 3, 2014 Category: Cancer & Oncology Authors: Nichols, H. B., DeRoo, L. A., Scharf, D. R., Sandler, D. P. Tags: Article Source Type: research
Cerebral venous thrombosis in a breast cancer patient taking tamoxifen: Report of a case
Conclusion Clinicians should warn about the possibility of thromboembolic complications with tamoxifen.
Source: International Journal of Surgery Case Reports - November 29, 2014 Category: Surgery Source Type: research
